DelveInsight’s “Osteosarcoma Market Insights, Epidemiology, and Market Forecast-2034” report offers an in-depth understanding of Osteosarcoma, historical and forecasted epidemiology as well as the Osteosarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Discover which therapies are expected to grab the Osteosarcoma Market Share @ https://www.delveinsight.com/sample-request/osteosarcoma-market
Key Takeaways from the Osteosarcoma Market Report
- In October 2025, OS Therapies’ candidate OST-HER2 demonstrated a significant improvement in overall survival among patients with recurrent, fully resected pulmonary metastatic osteosarcoma, with 75% of patients treated with the immunotherapy alive after two years, compared to 40% in the historical control group.
- In February 2026, OS Therapies initiated a Biologics License Application (BLA) submission to the US FDA for OST-HER2 aimed at preventing or delaying recurrent, fully resected pulmonary metastatic osteosarcoma.
- The Osteosarcoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034), driven by increasing prevalence and awareness of the disease.
- Osteosarcoma is a rare and aggressive type of bone cancer that typically develops in the long bones, such as the arms or legs, near the growth plates, primarily affecting children, teenagers, and young adults.
- Osteosarcoma is more common in males as compared to females, and is more common in children, teens, and young adults between the ages of 10 and 30, with only 1 in 10 osteosarcomas occurring in people older than 60.
- Among all the subtype-specific cases, approximately 80% were of conventional osteosarcoma in 2024.
- Among the 7MM, the United States has captured the highest market share of osteosarcoma in 2024.
- The leading Osteosarcoma Companies include Takeda, Y-mAbs Therapeutics, OS Therapies, AlaMab Therapeutics, CSPC Pharmaceutical, Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others.
- Key Osteosarcoma Therapies include MEPACT (mifamurtide), DANYELZA (naxitamab 15-096), OST-HER2 (OST31-154), ALMB-0168, Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, and Aldesleukine.
Stay ahead in the Osteosarcoma Therapeutics Market with DelveInsight’s Strategic Report @ https://www.delveinsight.com/sample-request/osteosarcoma-market
Osteosarcoma Epidemiology Segmentation in the 7MM
- Total Prevalence of Osteosarcoma
- Prevalent Cases of Osteosarcoma by Severity
- Gender-specific Prevalence of Osteosarcoma
- Diagnosed Cases of Episodic and Chronic Osteosarcoma
Download the report to understand which factors are driving Osteosarcoma Epidemiology trends @ https://www.delveinsight.com/sample-request/osteosarcoma-market
Osteosarcoma Marketed Drugs
- MEPACT (mifamurtide): Takeda
MEPACT is an established marketed therapy for osteosarcoma approved for use in combination with chemotherapy in pediatric and young adult patients.
- DANYELZA (naxitamab 15-096): Y-mAbs Therapeutics
DANYELZA is an FDA-approved therapy for the treatment of osteosarcoma, indicated for patients with recurrent or progressive disease.
- FUSILEV (levoleucovorin) and KHAPZORY (levoleucovorin)
FUSILEV and KHAPZORY are FDA-approved as “rescue” therapy after high-dose methotrexate treatment in osteosarcoma. FUSILEV was FDA approved in March 2008 and KHAPZORY was launched in 2019 as a lifecycle management extension of FUSILEV. After patent expiration of FUSILEV, clinicians continue to use either KHAPZORY or generic levoleucovorin, as all products have the same indication for methotrexate rescue in osteosarcoma.
- Second-line Therapies
The preferred second-line therapies (for relapsed/refractory or metastatic disease) by the NCCN include ifosfamide (high dose), etoposide, regorafenib, and everolimus.
Osteosarcoma Emerging Drugs
- OST-HER2 (OST31-154): OS Therapies
OST-HER2 is a Listeria monocytogenes-based immuno-oncology asset being developed for the prevention of recurrent, fully resected pulmonary metastatic osteosarcoma. The therapy was originally developed by Advaxis and fully acquired from Ayala Pharmaceuticals in April 2025. In January 2025, OS Therapies announced positive results from its Phase 2b trial (NCT04974008), which met its primary endpoint of 12-month event-free survival (EFS), showing a statistically significant improvement compared to historical controls. In October 2025, interim 1-year and 2-year data indicated a strong trend favoring overall survival (OS) in OST-HER2-treated patients, with 75% of patients alive after two years compared to 40% in the historical control group. In November 2025, OST-HER2 received the non-proprietary name “daznelimgene lisbac” from the WHO, marking an important milestone toward potential FDA approval. In December 2025, the FDA granted a waiver of the application fee for OST-HER2’s BLA submission, supporting accelerated regulatory development. In February 2026, OS Therapies initiated a Biologics License Application (BLA) submission to the US FDA for OST-HER2. In April 2026, the European Medicines Agency (EMA) initiated a rolling review for OST-HER2 for recurrent pulmonary metastatic osteosarcoma.
- ALMB-0168: AlaMab Therapeutics and CSPC Pharmaceutical
ALMB-0168 is an emerging therapeutic candidate in development for osteosarcoma treatment, representing a novel approach to address unmet needs in this ultra-rare pediatric indication.
- Additional Emerging Therapies
Other key emerging therapies in development include Olaparib (Dana-Farber Cancer Institute), Vactosertib (MedPacto, Inc.), ZN-c3 (K-Group, Beta, Inc.), Nivolumab (H. Lee Moffitt Cancer Center), HS-20093 (Hansoh BioMedical R&D Company), Cabozantinib (Ipsen), Afamitresgene autoleucel (Adaptimmune), and Aldesleukine (M.D. Anderson Cancer Center).
To learn more about Osteosarcoma treatment guidelines, visit @ https://www.delveinsight.com/sample-request/osteosarcoma-market
Osteosarcoma Competitive Landscape
The competitive landscape of the Osteosarcoma market is characterized by the presence of established pharmaceutical companies and emerging innovators focused on developing novel therapies for this rare and aggressive bone cancer. Market competition is driven by advancements in immunotherapy, targeted kinase inhibitors, and cell-based treatments. Key players are actively investing in research collaborations, pipeline expansion, and regulatory advancements to strengthen their market position and address significant unmet needs. The market is experiencing transformation through multiple-stage pipeline products that are expected to significantly revolutionize Osteosarcoma market dynamics. Companies are leveraging supportive regulatory frameworks, including orphan drug designations and fast-track approvals, to accelerate development of novel therapies. Rising focus on targeted therapies and immunotherapy for rare cancers, coupled with advancements in precision medicine and genomic profiling, is reshaping competitive strategies and improving treatment approaches across the 7MM.
Osteosarcoma Market Outlook
Osteosarcoma is a rare and aggressive type of bone cancer that typically develops in the long bones, such as the arms or legs, near the growth plates. It primarily affects children, teenagers, and young adults, though it can occur at any age. Symptoms include bone pain, swelling, and reduced joint movement. The exact cause is often unknown, but genetic factors and prior radiation exposure may contribute. Treatment usually involves a combination of surgery to remove the tumor and chemotherapy to target cancer cells. Early diagnosis and advanced treatments have improved survival rates, especially for localized cases. The Osteosarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteosarcoma pipeline products will significantly revolutionize the Osteosarcoma market dynamics.
Market growth is being driven by several key factors including increasing incidence of osteosarcoma, particularly among adolescents and young adults, rising focus on targeted therapies and immunotherapy for rare cancers, advancements in precision medicine and genomic profiling improving treatment strategies, and growing investment in oncology R&D and orphan drug development. Additionally, improved diagnostic techniques enabling early detection and intervention, supportive regulatory frameworks including orphan drug designations and fast-track approvals, and expanding pipeline of novel therapies including kinase inhibitors and cell-based treatments are expected to drive significant market expansion through 2034.
However, market barriers include the limited patient population due to the rare nature of the disease, high failure rates in clinical trials for new therapies, lack of significant breakthroughs compared to other cancer types, high cost of advanced treatments such as targeted therapies and immunotherapies, severe side effects associated with chemotherapy and combination treatments, challenges in conducting large-scale clinical trials due to small patient pool, and limited awareness and delayed diagnosis in certain regions.
Learn more about the emerging therapies for Osteosarcoma @ https://www.delveinsight.com/sample-request/osteosarcoma-market
Scope of the Osteosarcoma Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Forecast Period- 2020-2034
- Osteosarcoma Companies- Takeda, Y-mAbs Therapeutics, OS Therapies, AlaMab Therapeutics, CSPC Pharmaceutical, Dana-Farber Cancer Institute, MedPacto, Inc., K-Group, Beta, Inc., H. Lee Moffitt Cancer Center, Hansoh BioMedical R&D Company, Ipsen, UNICANCER, Adaptimmune, M.D. Anderson Cancer Center, and others.
- Osteosarcoma Pipeline Therapies- MEPACT (mifamurtide), DANYELZA (naxitamab 15-096), OST-HER2 (OST31-154), ALMB-0168, Olaparib, Vactosertib, ZN-c3, Nivolumab, HS-20093, Cabozantinib, cisplatin, Afamitresgene autoleucel, Aldesleukine, and others.
- Osteosarcoma Therapeutic Assessment: Osteosarcoma current marketed and Osteosarcoma emerging therapies
- Osteosarcoma Market Dynamics: Osteosarcoma market drivers and Osteosarcoma market barriers
- Osteosarcoma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Osteosarcoma Unmet Needs, KOL’s views, Analyst’s views, Osteosarcoma Market Access and Reimbursement
Table of Content
- Key Insights
- Report Introduction
- Executive Summary of Osteosarcoma
- Key Events of Osteosarcoma
- Epidemiology and Market Forecast Methodology
- Osteosarcoma: Market Overview at a Glance
- Disease Background and Overview: Osteosarcoma
- Treatment and Guidelines
- Epidemiology and Patient Population
- Patient Journey
- Marketed Drugs
- Emerging Drugs
- Osteosarcoma: Market Size
- Unmet Needs of Osteosarcoma
- SWOT Analysis of Osteosarcoma
- KOL Views of Osteosarcoma
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
